Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a noble gas protect the heart during bypass surgery?

NCT ID NCT01294163

Disease control Sponsor: Air Liquide Santé International Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 22, 2026 · Last updated Jul 23, 2026 · Updated 1 time

Summary

This trial tests whether the gas xenon can reduce heart muscle damage during coronary artery bypass surgery compared to two standard anesthetics: sevoflurane and propofol. About 500 adults with coronary artery disease scheduled for elective bypass surgery will be randomly assigned to one of the three anesthesia methods. The main measure is the level of troponin I in the blood 24 hours after surgery, a marker of heart injury.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
xenon gas, sevoflurane gas, or propofol intravenous anesthetic
What this could lead to
If xenon proves as good as or better than standard anesthetics, it could become a preferred option for heart surgery patients, potentially reducing heart damage after the procedure.
What could go wrong
This is a phase 3 trial, but xenon is already used in some countries. The main risk is that xenon may not protect the heart any better than existing options, and it is expensive and requires special equipment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

509 people

The number who actually took part.

Start date

Apr 2011

Finished

Apr 2014

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * coronary artery disease * elective surgery, planned coronary artery bypass graft * moderate hypothermia or normothermia * cardiac arrest cold and warm cardioplegia * normal of moderately impaired left ventricular systolic function * written informed consent Exclusion Criteria: * pregnancy or child bearing potential * ongoing treatment with nicorandil or sulfonylurea medication * severe renal or hepatic dysfunction * ongoing myocardial infarction or unstable angina

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Coronary artery bypass graft surgery are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

coronary artery disorder drug allergy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Coronary artery bypass graft surgery Coronary artery disease General anesthetic drug allergy

Contacts and locations

Locations

  • Academic Medical Center - University of Amsterdam

    Amsterdam, 1100 DD, Netherlands

  • CHU de Caen

    Caen, 14033, France

  • Centre Hospitalier de Rangueil

    Toulouse, 31059, France

  • Centre Hospitalo-Universitaire Pitié-Salpetrière

    Paris, 75013, France

  • Hôpital Cardiovasculaire et Pneumologique Louis Pradel

    Bron, 69677, France

  • Hôpital G&R Laennec - Centre Hospitalier Universitaire de Nantes

    Nantes, 44093, France

  • Hôpital Pontchaillou

    Rennes, 35033, France

  • Hôpital du Haut-Lévêque

    Pessac, 33600, France

  • Hôpitaux Universitaires de Strasbourg - Nouvel Hôpital Civil

    Strasbourg, 67091, France

  • Klinikum Links der Weser - Senator-Wessling-Str. 1

    Bremen, 28277, Germany

  • Policlinico Umberto I

    Rome, 00161, Italy

  • Thorax Center - Erasmus MC

    Rotterdam, 3000 CA, Netherlands

  • UniversitatsKlinikum Schleswig-Holstein

    Lübeck, 23538, Germany

  • University Hospital Aachen

    Aachen, 52074, Germany

  • University Hospital Frankfurt AM Main

    Frankfurt, 60590, Germany

  • University Hospital ROSTOCK

    Rostock, 18057, Germany

  • Universitätsklinikum Schleswig-Holstein

    Kiel, Schleswig-Holstein, 24105, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.